MetaVia reported all active patients in Phase 1 Part 3 have completed dose titration and reached target doses, with topline data on track for Q4 2026.
Key Highlights:
- All enrolled active patients in Part 3 completed dose titration and are now on highest target doses of 48 mg and 64 mg.
- Part 3 includes two 16-week titration cohorts: Part 3A (16→48 mg) and Part 3B (16→32→64 mg) to optimize tolerability.
- Planned enrollment ~40 subjects (≈20 per part), randomized 4:1 (16 active; 4 placebo) to assess safety, PK/PD and metabolic endpoints.
- Topline data readout for Part 3 remains on track for release in the fourth quarter of 2026.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.